By Barbara Arone, Vice President, Real World Solutions, IQVIA The use of real-world evidence (RWE) in the development of pharmaceutical treatments has grown exponentially in the past 10 years, fueled by availability of higher quality data, trial competitiveness and growing investments in personalized and
More
As we step into 2024, the global life science industry finds itself
By Michael von Papen, Chief Expert at Pharmatec GmbH – a Syntegon
The pharmaceutical industry is constantly shifting, as consumers seek the best treatments. As the market demands new solutions, drugmakers are
More
Ensuring the safety and efficacy of pharmaceutical products is paramount in the healthcare industry. Pharmaceutical impurity reference standards play a
MoreBy Michael von Papen, Chief Expert at Pharmatec GmbH – a Syntegon Company When a leading global collagenase manufacturer wants
More
By Justin Kozak, Executive VP & Life Sciences Lead, Founder Shield The tide is turning in the once-booming biotech industry. Funding slowdowns and
More
With the rapid development of biotechnology and molecular medicine, the introduction of mRNA as a vaccine or therapeutic agent enables
More
By Barbara Arone, Vice President, Real World Solutions, IQVIA The use of real-world evidence (RWE) in the development of pharmaceutical
MoreAs we step into 2024, the global life science industry finds itself at a crossroads, facing plenty of challenges alongside
More
